The most ideal guidelines for performing bone scans in prostate cancer staging in Taiwan  by Chien, Tsu-Ming et al.
Abstracts / Urological Science 26 (2015) S1eS25S6procedures within a post treatment 180-day follow-up period was
analyzed by quartile. A nested case-control study was also performed.
Results: 1,259 patients were eligible for ﬁnal analyses. During 3,980 per-
son-years follow-up, 167 patients had recurrent urolithiasis needed for
surgical intervention. From ﬁrst to fourth quartile of drug exposure,
recurrence rates were 45.64, 47.19, 43.11, and 18.52 per 1,000 person-years.
The adjusted hazard ratio was 0.46 (95% CI ¼ 0.24 to 0.89) for the fourth
quartile (vs. quartile 1). In the nested case-control study, adjusted ORs was
0.23 (95% CI ¼ 0.10 to 0.53) in the fourth quartile (vs. quartile 1).
Conclusion: Use of a-blockers for 180 days or more decrease the risk of
recurrent urolithiasis needed for surgical intervention. In patients at
higher risk of recurent urolithiasis, long term prescription of a-blockers
might help them prevent further surgical intervention.
PD3-5:
WILL THE RISKS OF POSTOPERATIVE INFECTION BE INCREASED AFTER
URETEROSCOPIC LITHOTRIPSY FOR PATIENTS WITH MILD PYURIA
BEFORE THE OPERATION?
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Wu 1,2,3, Yen-Hwa Chang 1,2,3, Alex T.L. Lin 1,2,3, Kuang-Kuo
Chen 1,2,3. 1Department of Urology, Taipei Veterans General Hospital,
Taiwan; 2Department of Urology, School of Medicine, National Yang-Ming
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Purpose: We evaluated whether the risks of postoperative infection will
be increased in patients with mild pyuria before ureteroscopic lithotripsy
(URSL) in a prospective study.
Materials and Methods: We prospectively enrolled patients receiving
URSL from 2011/5 to 2015/2. The patients with normal urine routine
(sediment WBC 5/HPF) before URSL were assigned as control, and those
with mild pyuria (sediment 5/HPF < WBC 50/HPF ) as experimental
group. Febrile UTI, patients < 18 years, pregnant, and urine sediment WBC
> 50/HPF were excluded. All patients received same protocol of preoper-
ative and postoperative antibiotics. Pre-, intra-operative, and post-opera-
tive urine routine and culture were collected. Peri-operative data were
compared. Post-operative pyuria, febrile episodes, and percentage of
emergency room visits were also compared.
Results: 140 patients were enrolled (experimental: 53, control: 87). Mean
age was 56.6 and 55.5 years, respectively. Patient's BMI, stone laterality,
stone location, and percentage of male patients were similar in both
groups. The mean stone size was 0.84cm vs. 0.76cm (p ¼ 0.243). The
operation duration was 58.8 vs. 49.2 min (p ¼ 0.022). The stone free rate
was 92.5% vs. 90.8%(p ¼ 0.235). Four out of 23 patients in experimental
group had positive pre-operative urine culture, two were E Coli, and two
Gram positive coccus. Two out of 12 patient in control group had positive
pre-operative urine culture, one was E. Coli and one was coagulase nega-
tive staphylococcus group. Two out of 33 patients had positive intra-
operative urine culture in experimental group: one pseudomonas, one
enterococcus species. One out of 46 patients had positive intra-operative
urine culture which was enterococcus species. Both pre-operative culture
and intra-operative culture didn't reach statistical signiﬁcance(p ¼ 0.398,
0.477 respectively). Two patients (3.8%) in the experiment group and none
in control group had post-operative fever but didn't reach statistical sig-
niﬁcance (p ¼ 0.068).
Conclusion: The incidence of postoperative fever increased in patients
with mild pyuria before URSL but didn't reach signiﬁcance compared to
patients with sterile urine.
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Purpose: To assess the safety of outpatient extracorporeal shock wave
lithotripsy (ESWL) in the management of patients with renal and ureteral
stones.
Materials and Methods: Between February 2012 and November 2014, 844
outpatients were treated with Outpatient ESWL at Taipei Veterans General
Hospital. 22 patients visited emergency department (ED) within 48 hours.
Stone size, stone shape (long to short axis ratio), location, total pulse of
shockwaves, stone management and urine analysis data and date before
ESWL, complications and treatment at ER and admission rate was inves-
tigated. Chi-Square and Logistic Regression analyses were used, with
p<0.05 set as the level of signiﬁcance.
Results: Of the 844 initial consecutive patients who underwent ESWL,
1095 times of ESWL was performed totally. There were 22(2%) patients
visited ED within 48 hours after ESWL. Mean Age was 54.3± 12.6 years
old; BMI was 25.9± 3.2; pre-ESWL Cr was 0.89± 2.54 mg/ml; post-
ESWL Cr was 1.04 ± 0.23 mg/ml; stone height/width ratio was
1.80± 0.57. The mean renal stone size was 12.2 ± 5.9 mm;. The mean
ureteral stone size was 6.1 ± 0.2 mm. 8 (8/379 ¼ 2.1%) patients had right
side stone, 14 (14/465 ¼ 3.0%) patients had left side stones. 16 patients
received ESWL for renal stone, 5 patients for ureter stone and 1 patient
for both. The most common complication was ﬂank pain include 16
patients (72.7%). Other complication includes hematuria (5 patients, all
from renal stone), fever (4 patients, all from renal stone), acute urinary
retention and nausea with vomiting (1 patient each). There were 12
patient received EWSL, PCNL, or URSL before. In 22 patient back to ER, 7
patients admitted to ward and 1 patient back to ER twice continuously.
All patients received medical treatment without ESWL or surgical
management.
Conclusion: The 48 hours Emergency Department Visiting rate was 2%.
There was no severe morbidity or mortality case. The tendency risk factors
according to our study include renal stone, large stone height/width ratio,
pre-ESWL stone management. The conclusion showed the outpatient
ESWL is safe for treating renal and ureteral stones.Podium-4
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PD4-1:
THE MOST IDEAL GUIDELINES FOR PERFORMING BONE SCANS IN
PROSTATE CANCER STAGING IN TAIWAN
Tsu-Ming Chien 1, Yen-Man Lu 1, Hung-Lung Ke 1,2, Shu-Pin
Huang 1,2, Chun-Nung Huang 1,2. 1Division of Urology, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan; 2 School of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan
Purpose: The necessity of bone scans in newly diagnosed prostate cancer
patients is still a matter of debate. We attempt to evaluate the validity of
currently published guidelines by analyzing bone scan results in newly
diagnosed prostate cancer (PCa) patients to determine the optimal staging
strategies.
Materials and Methods: Between January 2011 and July 2014, there were
362 consecutive newly diagnosed PCa patients at Kaohsiung Medical
University Hospital. Bone scans were performed for all patients at initial
staging. Patients positive for bone metastasis were characterized at diag-
nosis in terms of age, prostate-speciﬁc antigen (PSA) level, Gleason score
(GS), and clinical stage. We analyzed the sensitivity and speciﬁcity of the
American Urological Association (AUA) best practice policy, European As-
sociation of Urology guidelines, National Comprehensive Cancer Network
guidelines, and the classiﬁcation and regression tree by Briganti et al. for
diagnostic performance in predicting bone metastasis.
Results: A total 73 of 362 (20.2%) patients were diagnosed with bone
metastasis. Patients positive for metastasis on bone scans had signiﬁcantly
higher PSA levels (943.6 ± 2198.4 ng/mL vs. 56.1± 183.1 ng/mL; p < 0.001)
and higher GSs (8.5± 1.0 vs. 7.0± 1.6; p < 0.001) than those with negative
bone scan results. Pairwise comparisons in receiver operating curve
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curve than did the other guidelines.
Conclusion: The current AUA guidelines for the recommendation of
staging bone scans had better prediction and application rates than other
guidelines in our patient cohort.
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Purpose: Brachytherapy with permanent implant of radioactive seeds is
one of the ﬁrst-line treatments of localized prostate cancer. In Taiwan, this
treatment hasn't been provided in the past years. We conducted a Phase I
clinical trial to observe if we can preform it in good quality.
Materials and Methods: The clinical trial was conducted in KFSYSCC. In-
clusion criteria were: Patients with histologically conﬁrmed, localized
adenocarcinoma of the prostate, clinical stage T1c-2bN0M0, PSA < 20 ng/
ml, Gleason Score < 7, Karnofsky Performance Status > 70, No signiﬁcant
obstructive symptoms, No hip prosthesis, No prior transurethral prostate
surgery, No prior chemotherapy or radiotherapy or hormonal therapy,
prostate volume by trans-rectal ultrasound < 45 cc. Permanent implant of
I-125 seeds with prescription dose of 145Gy were given under general
anesthesia. PSA, IPSS score and IIEF score were recorded in 1, 3, 6, 9, 12 and
every 6 months after treatment.
Results: From May 2013 to April 2014, a total of 11 patients received I-125
seed implant brachytherapy. Clinical stages were T1c, T2a, T2b in 3, 7 and 1
patients each. Gleason Scores were 3+3 in 9 patients and 3+4 in 2 patients.
Pre-treatment PSA was less than 10ng/ml in 7 patients, and between 10-
20ng/ml in 4 patients. Clinical risk groups were low-risk in 7 patients and
intermediate-risk in 5 patients. Complications included 3 patients with
transient urine retention. At 1 year after seed implant, PSAdeclined to<1,1-
2, >2 in 6, 2, 3 patients each. IPSS returned to baseline level in 6-9 months.
IIEF returned to baseline level in 6 of 9 sexually active patients in 1 year.
Conclusion: Seed implant brachytherapy can be done in good quality for
the treatment of prostate cancer in Taiwan.
PD4-3:
THE SHORT-TERM EFFICACY AND SAFETY OF ABIRATERONE ACETATE
WITH PREDNISONE IN METASTATIC CASTRATION-RESISTANT PROSTATE
CANCER PATIENTS IN VGHTC
Chi-Feng Hung, Cheng-Kuang Yang, Yen-Chuan Ou, Hao-Chung Ho, Chen-
Li Cheng, Kun-Yuan Chiu, Chung-Kuang Su, Shian-Shiang Wang, Chuan-
Shu Chen, Jian-Ri Li, Cheng-Che Chen. Divisions of Urology, Department
of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
Purpose: To report short-term efﬁcacy and safety of abiraterone acetate
and prednisone in metastatic castration-resistant prostate cancer patients
in VGHTC.
Materials and Methods: A total of 25 patients with metastatic castration-
resistant prostate cancer who have progressive disease or have become
intolerance while receiving docetaxel were treated with abiraterone
(1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients
achieving a prostate-speciﬁc antigen (PSA) reduction  50% were
considered as PSA response, as COU-AA301 deﬁnition.
Results: There were 14 patients (56%) achieving PSA response, 6 (24 %)
having stable disease, and ﬁve (20 %) PSA progression, respectively. The
most common adverse event was hypokalemia (12%) and liver function
abnormalities (12 %). But hyperkalemia developed in two patients (8%).
Grade 3/4 adverse event was observed in one patient (4%).
Conclusion: Abiraterone acetate with prednisolone is potentially a favor-
able treatment in patients with metastatic castration-resistant prostate
cancer after treatment failure with docetaxel-based chemotherapy.PD4-4:
COMPARE PROSTATE CANCER DETECTION RATE BETWEEN 12- AND 18-
CORE PROSTATE BIOPSY IN PATIENTS WITH NORMAL DRE AND SERUM
PSA LEVEL OF 4.0-20.0 NG/ML
Bo-RenWang, Cheng Che Chen, Yen-Chuan Ou, Chi-Feng Hung, Cheng-Kuang
Yang, Chen-Li Cheng, Hao-ChungHo, Kun-Yuan Chiu, Chung-Kuang Su, Shian-
Shiang Wang, Chuan-Shu Chen, Jian-Ri Li. Divisions of Urology, Department of
Surgery, Taichung Veterans General Hospital, Taiwan
Purpose: To compare 12 and 18 core trans-rectal ultrasound (TRUS)-bi-
opsy in patients with normal DRE (digital rectal exam) and PSA level of
4.0-20.0 ng/mL
Materials and Methods: Between 2009 to 2014, 346 patients whose DRE
were normal or rubber and serum PSA level between 4.0 and 20.0 ng/mL
underwent TRUS biopsy. Of those patients, 318 underwent 12-core biopsy
and 28 underwent 18-core biopsy. We compared the prostate cancer
detection rates and post-biopsy complications rate between the two groups.
Results: The baseline characteristics of the two groups were comparable
with regard to the mean age, prostate volume and PSA level, and PSA
density. In the 12-core prostate biopsy group, 36 (11.3%) patients were
found to have prostate cancer. On the other hand, in the 18-core prostate
biopsy group of patients, 4 (14.2%) were found to have prostate cancer.
There were no signiﬁcant different prostate cancer detection rate between
12-core biopsy and 18-core biopsy group. Besides, in patients with PSA
density (PSAD) < 0.2, the prostate cancer detection rate was slightly higher
in the 18-core biopsy group(14.3%) than in the 12-core biopsy group(9.6%),
but not statistically signiﬁcant. There was no signiﬁcant difference
complication rates as urinary retention or sepsis between the two groups.
Conclusion: We can't conclude that TRUS-guided 18-core biopsy of the
prostate is superior to the 12-core in patients with normal DRE and serum
PSA level of 4.0-20.0 ng/mL. Further studies in different population with
greater sample size are needed to draw ﬁnal conclusion.
PD4-5:
TGF-b1 MEDIATES THE RADIATION RESPONSE OF PROSTATE CANCER
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Radiotherapy is the main treatment modality for prostate cancer. This
study investigated the role of TGF-b1 in biological sequelae and tumor
regrowth following irradiation, which are critical for the clinical radiation
response of prostate cancer. Human and murine prostate cancer cell lines,
and corresponding hormone-refractory (HR) cells, were used to examine
the radiation response by clonogenic assays in vitro and tumor growth
delay in vivo. Biological changes after irradiation, including cell death and
tumor regrowth, were examined by experimental manipulation of TGF-b1
signaling. The correlations among tumor radiation responses, TGF-b1
levels, and regulatory T cells (Tregs) recruitment were also evaluated using
animal experiments. HR prostate cancer cells appeared more radio-
resistant and had higher expression of TGF-b1 compared to hormone-
sensitive (HS) cells. TGF-b1 expression was positively linked to irradiation
and radioresistance, as demonstrated by in vitro and in vivo experiments.
Inhibition of TGF-b1 increased tumor inhibition and DNA damage after
irradiation.When mice were irradiated with a sub-lethal dose, the
regrowth of irradiated tumors was signiﬁcantly correlated with TGF-b1
levels and Tregs accumulation in vivo. Furthermore, blocking TGF-b1
clearly attenuated Tregs accumulation and tumor regrowth following
treatment. These data demonstrate that TGF-b1 is important in deter-
mining the radiation response of prostate cancer, including tumor cell
killing and the tumor microenvironment. Therefore, concurrent treatment
with a TGF-b1 inhibitor is a potential therapeutic strategy for increasing
the radiation response of prostate cancer, particularly for more aggressive
or HR cancer cells.
